Breaking News

Financial Report: Dendreon

By Kristin Brooks | March 3, 2014

Revenues down 12% in the quarter


4Q Revenues: $74.8 million (-12%)

4Q Loss: $88.7 million (loss of $38.7 million 4Q12)

FY Revenues: $283.7 million (-13%)

FY Loss: $296.8 million (loss of $393.6 million FY12)

Comments: The company added 31 new accounts for PROVENGE in the quarter and implemented a new commercial model. The company will make PROVENGE available in Europe through Centers of Excellence using CMO PharmaCell, beginning with Germany and the UK. Royalty and other revenues were down to $7 million in the quarter, from $38 million in 4Q12.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks